Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics, Inc. director Terrie Curran reported option exercises and share sales. On August 27, 2026, Curran exercised stock options covering 38,200 shares of common stock at exercise prices of $7.51 and $8.63 per share, then sold the same 38,200 shares at a weighted average price of $25.0294 per share, with individual sale prices ranging from $25.00 to $25.1001.
Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that Terrie Curran intends to sell restricted common stock through Merrill Lynch. The notice covers 38,200 shares of common stock with an aggregate market value of $956,124.61, expected to be sold on or after August 27, 2026 on NASDAQ.
The shares relate to stock option exercises on May 31, 2023 for 11,148 shares and June 14, 2024 for 27,052 shares. In the preceding three months, Terrie Curran sold 1,072 shares of common stock for $27,912.35.
Arcutis Biotherapeutics, Inc. (ARQT) director Terrie Curran reported an option exercise-and-sale sequence. Curran exercised a stock option for 1,072 shares of common stock at an exercise price of $7.51 per share, then sold 1,072 shares of common stock at a weighted average sale price of $26.0376 per share in multiple trades between $26.00 and $26.2228. After the derivative transaction, Curran held 11,148 stock options directly, with the option described as fully vested and expiring on May 31, 2033.
Arcutis Biotherapeutics, Inc. (ARQT) reported that EVP and Chief Medical Officer Patrick Burnett sold 1,697 shares of common stock on 2026-08-19 at $27.00 per share. A footnote states the sale was made to cover tax withholding obligations related to vesting Restricted Stock Units, leaving him with 117,592 shares directly held.
Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that Terrie Curran plans to sell 1,072 shares of the company’s common stock. The shares are to be sold through Merrill Lynch on the NASDAQ, with cash as the form of payment and were acquired via a stock option exercise dated 05/31/2023.
Arcutis Biotherapeutics, Inc. (ARQT) director Howard G. Welgus reported option exercises and a share sale. He exercised fully vested stock options covering 4,096 shares of common stock at exercise prices of $6.5223, $7.51, and $8.63 per share, acquiring the same number of common shares. On the same date, he sold 4,730 shares of common stock at a weighted average price of $26.1807 per share, in multiple trades between $26.10 and $26.25, pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026 with a plan end date of June 15, 2027.
Arcutis Biotherapeutics, Inc. (ARQT) is the issuer of common stock that officer Patrick Burnett plans to sell under Rule 144. The notice covers a proposed sale of 1,697 shares of common stock, with an approximate aggregate market value of $45,819, and notes prior sales over the past three months.
Howard Welgus filed a Form 144 indicating a proposed sale through Merrill Lynch of 4,730 shares of Arcutis Biotherapeutics common stock, with an aggregate market value of $123,834.71, on or after August 17, 2026 on NASDAQ. The shares relate to restricted stock vesting of 634 shares on June 4, 2026 and stock option exercises of 822 shares (granted November 20, 2019), 1,019 shares (granted May 31, 2023), and 2,255 shares (granted June 14, 2024). In the prior three months, Welgus reported sales of 4,096 shares for $99,980.49 on June 15, 2026, 635 shares for $16,300.45 on June 17, 2026, and 4,730 shares for $127,284.30 on July 15, 2026.
Polar Capital Holdings Plc and Polar Capital LLP reported a significant ownership position in Arcutis Biotherapeutics, Inc. common stock. They collectively beneficially own 6,606,945 shares, representing 5.28% of the outstanding common stock, with sole voting and dispositive power over these shares and no shared power.
The ownership percentage is calculated based on 125,083,374 shares outstanding of Arcutis Biotherapeutics as reported in the company’s Form 10-Q filed on May 6, 2026. The filing is made as a joint Schedule 13G by Polar Capital entities, with the joint filing statement executed by Chief Operating Officer Nicholas Farren.
Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett reported an exercise-and-sell transaction in company stock. On August 11 and 12, 2026, he exercised stock options for a total of 15,000 shares of common stock at an exercise price of $3.64 per share and sold the same 15,000 shares in open-market transactions at weighted average prices of $26.52 and $26.08, respectively. The filing does not state his remaining share or option holdings.